• BioAge Labs dosed the first participant in QUELL-CV, a Phase 2 trial of oral NLRP3 inhibitor BGE-102 for cardiovascular risk reduction.
• Study will test three once-daily doses versus placebo in 160 adults with obesity and elevated inflammation.
• Readout will assess whether BGE-102 lowers systemic inflammation, guiding dose selection for a planned Phase 3 program.
• Phase 1 results were previously reported, showing the drug reduced inflammation and was well tolerated.
• Topline Phase 2 data are expected in the second half of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bioage Labs Inc. published the original content used to generate this news brief on June 16, 2026, and is solely responsible for the information contained therein.